A six-year-old girl has died in China after an experimental gene-editing therapy, and researchers quoted by the South China Morning Post are calling for stronger safeguards in clinical trials. Parts of the sector fear a regulatory backlash.
The case involves a six-year-old girl in China who died after receiving an experimental gene-editing therapy. It was reported by the South China Morning Post, which quoted scientists describing the death as a tragedy and arguing that clinical trials in the field need better safeguards. China has built a fast-growing biotech sector, and according to the newspaper some people working in it worry that the death will prompt a policy backlash against that boom. Details of the treatment, the trial and the cause of death have not been established in the available reporting.
A six-year-old girl died in China after receiving an experimental gene-editing therapy, a case that scientists quoted by the South China Morning Post called a tragedy showing the need for better safeguards in clinical trials. According to the newspaper, some in the sector fear the death will trigger a policy backlash against China's biotech boom.